Highly Galactosylated Anti-CD11a (Efalizumab) Antibody (CAT#: BioBet-GA-056ZP) Datasheet

CD11A

CD11A

ITGAL encodes the integrin alpha L chain. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. This I-domain containing alpha integrin combines with the beta 2 chain (ITGB2) to form the integrin lymphocyte function-associated antigen-1 (LFA-1), which is expressed on all leukocytes. LFA-1 plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAMs 1-3 (intercellular adhesion molecules 1 through 3), and also functions in lymphocyte costimulatory signaling. Involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. Contributes to natural killer cell cytotoxicity.

CD11A; LFA-1; ITGAL

Plasma membrane

Its related pathways are Integrin Pathway and Degradation of the extracellular matrix.

Integrin ITGAL/ITGB2 is the receptor for ICAM1, ICAM2, ICAM3 and ICAM4. The integrin ITGAL/ITGB2 is the receptor for F11R (PubMed:11812992, PubMed:15528364). Integin ITGAL/ITGB2 is the receptor for the secreted ubiquitin-like protein ISG15; this interaction is mediated by ITGAL (PubMed: 29100055). Participate in a variety of immune phenomena, including leukocyte-endothelial cell interaction, cytotoxic T cell-mediated killing, and antibody-dependent killing of granulocytes and monocytes. Contribute to natural killer cell toxicity (PubMed: 15356110). Participate in the adhesion and transport of leukocytes including T cells and neutrophils (PubMed:11812992). There is a need to generate common lymphoid progenitor cells in the bone marrow, demonstrating its role in lymphogenesis (through similarity). The integrin ITGAL/ITGB2 is related to ICAM3 and contributes to the phagocytosis of macrophages and neutrophils (PubMed:23775590).

In resting T-cells, up to 40% of surface ITGAL is constitutively phosphorylated. Phosphorylation causes conformational changes needed for ligand binding and is necessary for activation by some physiological agents.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

Efalizumab

Human

Human

Efalizumab, sold under the trade name Raptiva, is a drug previously used to treat autoimmune diseases. Efalizumab binds to the CD11a subunit of lymphocyte function-associated antigen 1, and was originally used to treat psoriasis. .

Moderate to Severe Chronic Plaque Psoriasis

anti-CD11a, antiCD11 alpha, Efalizumab

Efalizumab is a humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. CD11a is a subunit of leukocyte functional antigen 1 (LFA-1), which is expressed on all leukocytes. Efalizumab binds to the CD11a subunit of lymphocyte function-related antigen 1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration from blood vessels into tissues. As a result, Efalizumab reduced the cell surface expression of CD11a.

For the treatment of adult patients with moderate to severe chronic plaque psoriasis, these patients are suitable for phototherapy or systemic therapy.